Italia markets open in 1 hour 47 minutes

NUCANA SP.ADR 1/ LS-,04 (N04A.BE)

Berlin - Berlin Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
0,6750+0,0100 (+1,50%)
Alla chiusura: 08:18PM CEST
Schermo intero
Chiusura precedente0,6650
Aperto0,6550
Denaro0,5850 x 0
Lettera0,7100 x 0
Min-Max giorno0,6450 - 0,6750
Intervallo di 52 settimane0,5400 - 2,9000
Volume0
Media Volume0
CapitalizzazioneN/D
Beta (5 anni mensile)N/D
Rapporto PE (ttm)N/D
EPS (ttm)N/D
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    NuCana Announces Presentation on NUC-7738 at the European Hematology Association (EHA) 2022 Hybrid Congress

    NUC-7738 Shows Promising Non-Clinical Activity in Acute Myeloid Leukemia NUC-7738 Kills AML Cells Resistant to Standard Chemotherapy Data Indicates Potential Clinical Utility Beyond Solid Tumors EDINBURGH, United Kingdom, June 10, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced data to be presented at the European Hematology Association (EHA) 2022 Hybrid Congress highlighting the activity of NUC-7738, a phosphoramidate transformation of 3’-deoxyadenosine (3’-dA), in a broad range of

  • GlobeNewswire

    NuCana Announces Receipt of NASDAQ Notice

    EDINBURGH, United Kingdom, June 03, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that it received written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC ("Nasdaq") dated May 27, 2022, indicating that, based upon a closing bid price of less than $1.00 per share for the Company’s American Depositary Shares (“ADSs”) for the prior 30 consecutive business day period, the Company no longer satisfies Nasdaq Listing Rule 5450(a)(1). The Notification Letter has

  • GlobeNewswire

    NuCana Reports First Quarter 2022 Financial Results and Provides Business Update

    Initiated Randomized Phase 2 Study of NUC-3373 in Patients with Colorectal Cancer Initiated Phase 1b/2 Study of NUC-3373 in Combination with Other Agents, Including PD-1 Inhibitors, in Patients with Solid Tumors First Patients Enrolled in Phase 2 Study of NUC-7738 Multiple Data Readouts in 2022 Well Capitalized with Anticipated Cash Runway into 2025 EDINBURGH, United Kingdom, June 02, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the first quarter ended March